Friday, November 13, 2026

USD/CNH Over 1% Down In The Last 21 Sessions

USD/CNH Over 1% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.64% for the last 21 sessions. At 20:09 EST on Monday, 10 April, USD/CNH (USDCNH) is $6.89.

USD/CNH's yearly highs and lows, it's 0.007% up from its 52-week low and 0.059% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CNH's Forex is considered to be overbought (>=80).

News about

  • Eur/usd stays defensive around 1.0900 despite hawkish ecb, US inflation, fed minutes eyed. According to FXStreet on Sunday, 9 April, "While the fresh hawkish bets on the Fed and upbeat US data, as well as geopolitical woes, can pause the US Dollar weakness, the EUR/USD bears are far from the table and needs more clues to extend the upward trajectory amid the Easter Monday holidays.", "A 12-day-old rising wedge bearish chart formation, currently around 1.0860 and 1.1000, keeps EUR/USD bears hopeful."
  • Eur/usd forex signal: moderately bullish ahead of US CPI data - 10 April 2023. According to DailyForex on Monday, 10 April, "The EUR/USD has been calm since Friday as European and American countries celebrate the Easter holiday. ", "The EUR/USD pair rose to a high of 1.0973 on Wednesday and then pulled back to a low of 1.0877 on Friday. "
  • Eur/usd struggles to justify upbeat options market signals near 1.0900. According to FXStreet on Monday, 10 April, "Moving on, the Easter Monday holiday may restrict EUR/USD moves but the US Consumer Price Index (CPI) data and the latest Federal Open Market Committee(FOMC) Monetary Policy Meeting Minutes will be crucial for clear directions.", "That said, a one-month risk reversal (RR) of the EUR/USD price, a gauge of the spread between the call and put options, printed a mild daily gain to +0.020 by the end of Friday's North American session. "
  • Eur/usd forecast: overhead selling pressure - 10 April 2023. According to DailyForex on Monday, 10 April, "However, it is worth nothing that the EUR/USD is a great indicator of US dollar strength, and therefore an important signal."
  • Eur/usd price analysis: 10-dma prods intraday sellers, 1.0850 is the last defense for bulls. According to FXStreet on Monday, 10 April, "Meanwhile, a daily closing beyond 1.0930 isn't an open invitation to the EUR/USD bulls as the previous support line from mid-March, around 1.1015 by the press time, precedes the yearly high marked in January around 1.1035, to challenge further upside of the major currency pair.", "In a case where EUR/USD remains firmer past 1.1035, the late March 2022 high near 1.1185 will be in focus."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com